Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance

作者：Alame Emane A K; Xu P; Pierre Audigier C; Cadet Daniel V; Shen X; Sraouia M; Siawaya J F Djoba; Takiff H; Gao Q; Gicquel B^*

来源：International Journal of Tuberculosis and Lung Disease, 2015, 19(6): 679-684.

DOI：10.5588/ijtld.14.0768

• tuberculosis
• drug resistance
• pyrazinamide

BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern.
OBJECTIVE: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP).
DESIGN: Isolates from two major urban centres Paris (101 strains) and Shanghai (171 strains) were investigated for the association of pncA mutations with resistance to drugs other than PZA.
RESULTS: The proportion of pncA mutations found in INH-monoresistant strains was not increased.
CONCLUSION: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.

• 出版日期2015-6
• 单位复旦大学; 中国科学院上海巴斯德研究所; 河北医科大学; 上海市疾病预防控制中心